Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Northrop Grumman Corporation (NOC) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Northrop Grumman CorporationTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Northrop Grumman Corporation — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Northrop Grumman Corporation trades at $575 (market cap $82.10B). The key difference: Northrop Grumman Corporation is far larger — about 8.7× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIONOC
Market Cap
$9.39B$82.10B
Sector
HealthIndustrials
52-Week High
$356.25$768.02
52-Week Low
$241.71$496.02
Enterprise Value
$9.14B$96.08B
Dividend Yield
1.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Northrop Grumman Corporation

Northrop Grumman (NOC) trades at $571.58, up 0.68% on the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates with $7.68 actual versus $6.82 expected, and raised full-year guidance amid a record $105 billion backlog. Fundamentals show robust profitability with a 10.48% net income margin and 26.96% ROE, while valuation metrics like a P/E of 18.17 appear reasonable relative to growth.

Outlook remains positive given defense spending tailwinds and contract wins like the $7.6 billion Sentinel program, though margin pressures and high debt levels pose risks. Analysts are bullish with a $598.57 consensus target, implying ~5% upside from current levels, supported by 20 buy ratings versus 1 sell.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Northrop Grumman Corporation

Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.

Read more on NOC